ReviewMolecular medicine reports2025
Insulin‑like growth factor in cancer: New perspectives (Review).
Review in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Molecular interplay of insulin resistance and cancer: advances in monoclonal antibody therapeutics.Cancer biology & therapy · 2026Review
- Genetic Variability in the IGF-1 Axis Modulates Cancer-Associated Cachexia and Prognosis.Cancers · 2026Article
- The insulin receptor inhibitor BMS-754807 alleviates neuroinflammation and Alzheimer's disease pathologies across human cellular and mouse models.Journal of neuroinflammation · 2026Article
- Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Bidirectional Interactions Between Immune Regulation and the Insulin-like Growth Factor Axis in Colorectal Cancer.International journal of molecular sciences · 2026Review
- Mechanistic insights and clinical implications of RNA-binding proteins in prostate cancer.Discover oncology · 2026Review
- The impact of genetic variants of the IGF-1 axis on surgical outcomes and prognosis in ovarian cancer.Molecular biology reports · 2026Article
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026Review
- Assessing the Role of Lifestyle in Modulating Serum IGF-1 and Association with Breast Cancer Risk among Palestinian Women in the Gaza Strip: A Case-Control Study.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- The endocrine role of hepatokines: implications for human health and disease.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complex nature and heterogeneity of cancer present challenges for cancer treatment. As a class of single‑chain peptides, insulin‑like growth factors (IGFs) play key roles in cell growth, proliferation, differentiation and metabolic regulation. IGFs promote the proliferation, migration and invasive ability of tumor cells and are closely associated with poor prognosis. Furthermore, IGFs can influence the interactions between immune cells in the tumor microenvironment leading to immune escape. Moreover, the activation of signals associated with IGFs mediates the resistance of tumor cells to chemotherapeutic drugs. With the increasing incidence of tumor events, the desire for new therapies is becoming more urgent. This article comprehensively summarizes the molecular biological mechanisms of IGFs in tumorigenesis and the development of therapies related to targeting IGFs, with the hope of providing new insights into cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.